Show simple item record

dc.contributor.authorCooke, Vesselina G.
dc.contributor.authorLeBleu, Valerie Sandra
dc.contributor.authorKeskin, Doruk
dc.contributor.authorKhan, Zainab
dc.contributor.authorO’Connell, Joyce T.
dc.contributor.authorTeng, Yingqi
dc.contributor.authorDuncan, Michael B.
dc.contributor.authorXie, Liang
dc.contributor.authorMaeda, Genta
dc.contributor.authorVong, Sylvia
dc.contributor.authorSugimoto, Hikaru
dc.contributor.authorRocha, Rafael M.
dc.contributor.authorDamascena, Aline
dc.contributor.authorBrentani, Ricardo R.
dc.contributor.authorKalluri, Raghu
dc.date.accessioned2014-12-01T15:09:02Z
dc.date.available2014-12-01T15:09:02Z
dc.date.issued2012-01
dc.date.submitted2011-09
dc.identifier.issn15356108
dc.identifier.urihttp://hdl.handle.net/1721.1/91948
dc.description.abstractThe functional role of pericytes in cancer progression remains unknown. Clinical studies suggest that low numbers of vessel-associated pericytes correlated with a drop in overall survival of patients with invasive breast cancer. Using genetic mouse models or pharmacological inhibitors, pericyte depletion suppressed tumor growth but enhanced metastasis. Pericyte depletion was further associated with increased hypoxia, epithelial-to-mesenchymal transition (EMT), and Met receptor activation. Silencing of Twist or use of a Met inhibitor suppressed hypoxia and EMT/Met-driven metastasis. In addition, poor pericyte coverage coupled with high Met expression in cancer cells speculates the worst prognosis for patients with invasive breast cancer. Collectively, our study suggests that pericytes within the primary tumor microenvironment likely serve as important gatekeepers against cancer progression and metastasis.en_US
dc.description.sponsorshipNational Institutes of Health (U.S.) (NIH Grant CA125550)en_US
dc.description.sponsorshipNational Institutes of Health (U.S.) (NIH grant CA155370)en_US
dc.description.sponsorshipNational Institutes of Health (U.S.) (NIH Grant CA151925)en_US
dc.description.sponsorshipNational Institutes of Health (U.S.) (NIH Grant DK81576)en_US
dc.description.sponsorshipNational Institutes of Health (U.S.) (NIH Grant CA163191)en_US
dc.description.sponsorshipNational Institutes of Health (U.S.) (NIH grant DK55001)en_US
dc.description.sponsorshipChampalimaud Foundation (Champalimaud metastasis programme)en_US
dc.description.sponsorshipChampalimaud Foundation (Champalimaud investigator)en_US
dc.description.sponsorshipNational Institutes of Health (U.S.) (NRSA F32 Ruth Kirschstein Postdoctoral Fellowship from NIH/NIDDK (5F32DK082119-02))en_US
dc.description.sponsorshipNational Institutes of Health (U.S.) (NIH Research Training Grant in Gastroenterology (2T32DK007760-11))en_US
dc.description.sponsorshipNational Institutes of Health (U.S.) (NIH Research Training Grant in Cancer Biology (5T32CA081156-08))en_US
dc.description.sponsorshipUnited States. Dept. of Defense (DoD Breast Cancer Research Predoctoral Traineeship Award (W81XWH-09-1-0008))en_US
dc.description.sponsorshipNational Institutes of Health (U.S.) (NIH Research Training Grant in Cardiovascular Medicine (5T32HL007374-30))en_US
dc.description.sponsorshipUnited Negro College Fund/Merck (Postdoctoral Science Research Fellowship)en_US
dc.description.sponsorshipNational Institutes of Health (U.S.) (NIH supplemental grant (CA125550))en_US
dc.language.isoen_US
dc.publisherElsevier B.V.en_US
dc.relation.isversionofhttp://dx.doi.org/10.1016/j.ccr.2011.11.024en_US
dc.rightsArticle is made available in accordance with the publisher's policy and may be subject to US copyright law. Please refer to the publisher's site for terms of use.en_US
dc.sourceElsevieren_US
dc.titlePericyte Depletion Results in Hypoxia-Associated Epithelial-to-Mesenchymal Transition and Metastasis Mediated by Met Signaling Pathwayen_US
dc.typeArticleen_US
dc.identifier.citationCooke, Vesselina G., Valerie S. LeBleu, Doruk Keskin, Zainab Khan, Joyce T. O’Connell, Yingqi Teng, Michael B. Duncan, et al. “Pericyte Depletion Results in Hypoxia-Associated Epithelial-to-Mesenchymal Transition and Metastasis Mediated by Met Signaling Pathway.” Cancer Cell 21, no. 1 (January 2012): 66–81. © 2012 Elsevier Inc.en_US
dc.contributor.departmentHarvard University--MIT Division of Health Sciences and Technologyen_US
dc.contributor.mitauthorKalluri, Raghuen_US
dc.relation.journalCancer Cellen_US
dc.eprint.versionFinal published versionen_US
dc.type.urihttp://purl.org/eprint/type/JournalArticleen_US
eprint.statushttp://purl.org/eprint/status/PeerRevieweden_US
dspace.orderedauthorsCooke, Vesselina G.; LeBleu, Valerie S.; Keskin, Doruk; Khan, Zainab; O'Connell, Joyce T.; Teng, Yingqi; Duncan, Michael B.; Xie, Liang; Maeda, Genta; Vong, Sylvia; Sugimoto, Hikaru; Rocha, Rafael M.; Damascena, Aline; Brentani, Ricardo R.; Kalluri, Raghuen_US
mit.licensePUBLISHER_POLICYen_US
mit.metadata.statusComplete


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record